Q2 2025 Laurus Labs Ltd Earnings Call Transcript
Key Points
- Laurus Labs Ltd (BOM:540222) reported a healthy gross margin of 55% for Q2, indicating strong product mix and operational efficiency.
- The company has commenced operations at a new R&D center in Hyderabad, enhancing its development and manufacturing capabilities.
- Laurus Labs Ltd (BOM:540222) is working on over 90 active projects, with a significant focus on human health, animal health, and crop production.
- The CDMO division recorded an 8% growth, driven by resource allocation towards high-value complex programs.
- The company successfully passed multiple quality audits, including a US FDA inspection, without any critical findings, showcasing its commitment to quality standards.
- EBITDA margins were subdued at 15% due to lower asset utilization and dilution from growth initiatives.
- Generic API revenues declined by 11% in Q2, primarily due to lower demand in the oncology portfolio and a planned facility shutdown.
- The company is experiencing operational leverage issues, which have been affecting margins for several quarters.
- Debt levels have increased to INR 2,700 crore, with operating cash flow remaining negligible in the first half.
- The formulation division saw a marginal 2% decrease in revenues, impacted by lower volume uptake in certain markets.
Ladies and gentlemen, good day. And welcome to Laus Labs Limited Q2 F 525 earnings conference call hosted by Antique Stock broking.
(Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr Moni Shaha from Antique stockbroking. Thank you and over to you, sir.
Yeah. Thank you, Dle, good evening, everyone and welcome to Laus Labs two QN one HF I '25 results conference call. Today we have with us, Doctor Satna Anda founder and CEO Mr V Ravikumar, executive director and CFO and from the IR team on behalf of Antique. So working, I would like to thank the Los management for giving us the opportunity to host this call.
I would now like to hand the call over to doctor Satya for his opening remarks. Thank you and over to you, sir.
Thank you Manish for the introduction We welcome you all to the Q2 fa '25 and the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
